AI-Driven Modeling and Optimization of Drug Delivery and Pharmacokinetic Processes

Mohammed Eltahir Abdelhag[1], Nahid Mahmoud Hassan Elamin[2], Badreldin S. R. Ahmed[3], Hind Ali Osman[4], Abeer Mohamed Saleh Atout[5], Mohammed Hassan Osman Abdalraheem[6], Emad Addin Alsheikh[7], Saad Mamoun AbdelRahman Ahmed[8]

[1]Department of Computer Science, College of Engineering and Computer Science, Jazan University, Jazan, Saudi Arabia. Email: mohedtahir@gmail.com, mabdelhag@jazanu.edu.sa

[2]Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Saudi Arabia. Email: nelamin@jazanu.edu.sa

[3]Department of Medical Laboratory Technology, College of Nursing and Allied Health Sciences, Jazan University, Saudi Arabia. Email: brahama@jazanu.edu.sa

[4]Department of Preventive Dental Science, College of Dentistry, Jazan University, Saudi Arabia. Email: haosman@jazanu.edu.sa

[5]College of Dentistry, Jazan University, Jazan, Saudi Arabia. Email: Aatout@Jazanu.edu.sa ORCID: 0000-0002-7800-738X

[6]Department of Computer Science, College of Engineering and Computer Science, Jazan University, Saudi Arabia. Email: mohammedh@jazanu.edu.sa

[7]Department of Computer Science, Middle East University, Amman 11118, Jordan. Email: e.alsheikh@meu.edu.jo

[8]Applied College, King Faisal University, P.O. Box 400, Al-Ahsa 31982, Saudi Arabia. Email: smaahmed@kfu.edu.sa

Abstract- The combination of artificial intelligence (AI) and pharmacokinetic (PK) and drug delivery study is a paradigm shift in computational pharmaceutics. In this paper, a detailed AI-driven framework of the modeling, prediction, and optimization of drug delivery systems and pharmacokinetic processes are described. We systematize and test a body of interconnected methodologies which include machine learning ensemble methods, directed message-passing graph neural networks (D-MPNN) as well as the Long Short-Term Memory (LSTM) recurrent architecture, Neural Ordinary Differential Equations (Neural ODEs), hybrid AI-physiologically based pharmacokinetic (PBPK) models, Bayesian optimization, multi-objective evolutionary algorithms, and reinforcement learning-based adaptive dosing agents to the prediction of absorption, distribution, metabolism, and excretion (ADME The hybrid Neural ODE-PBPK model described here, when benchmarked against established tools (Phoenix WinNonlin, PK-Sim, Simcyp) has a root mean square error (RMSE) of 21.3 ng/mL, coefficient of determination R2 = 0.951 and geometric mean fold error (GMFE) of 1.63 - all large improvements over its classical counterparts. The Mean time-in-therapeutic range is 78.4 percent (25.2) using the Soft Actor-Critic reinforcement learning dosing agent as compared to 61.2% (23.6) with standard weight-based dosing. Nanoparticle formulations with improved drug loading efficiency (3.4 fold) are bayesian-optimized. The model provides a stringent, repeatable and regulation conscious basis of AI-based accuracy pharmacotherapy.

Keywords- Pharmacokinetics, Drug Delivery, Machine Learning, Graph Neural Networks, Neural ODE PBPK, Reinforcement Learning, Bayesian Optimization, Precision Medicine, ADME Prediction

How to cite this article: Abdelhag ME, Elamin NMH, Ahmed BSR, Osman HA, Atout AMS, Abdalraheem MHO, Alsheikh EA, Ahmed SMA. AI-Driven Modeling and Optimization of Drug Delivery and Pharmacokinetic Processes. Int J Drug Deliv Technol. 2026;16(21s): 940-951. DOI: 10.25258/ijddt.16.21s.99

1. Introduction

Every rational drug therapy decision is based on the science of pharmacokinetics, the quantitative study of drug absorption, distribution, metabolic, and excretion in the body, whether it is the choice of an initial dose in the initial clinical trials or how an individual dose should be increased or decreased in the complex populations of patients [1]. Together with the pharmacodynamics, or description of the concentration-dependent biological effect caused by a drug, the unified PK/PD model offers the necessary quantitative interpolation between the dose given and the therapeutic or toxic outcome [2]. Although decades of methodological advancement and extensive use of

nonlinear mixed-effects (NLME) frameworks of population pharmacokinetics modeling have been achieved, fundamental limitations remain that move satisfactorily towards constraints on the capacity of classical methods to satisfy modern drug discovery and personalized clinical pharmacology needs [3].

Classical ODE systems Classical ODE systems (one-compartment and two-compartment) as well as non-compartmental analysis (NCA) and even mechanistically detailed physiological based pharmacokinetic (PBPK) models all have a common weakness: they are parametric, assumption-based models that encode particular structural assumptions about the biological system and are not capable of adapting the model in response to data that contradicts those assumptions [4]. The sheer magnification of biomedical data, both in high-throughput molecular screening campaigns to generate millions of compound-activity data, to population-scale electronic health records to encode longitudinal drug exposures and outcomes data, to wearable biosensor systems to provide continuous physiological measurements has generated data resources of a quality, quantity, and complexity to which the traditional PK conceptual frameworks are structurally unprepared to be used. Paradoxically, this abundance of data coupled with model inadequacy has generated the pressing incentive and also the facilitating circumstance, to the integration of artificial intelligence to pharmacokinetic science [5]. Artificial intelligence and subdisciplines, including machine learning, deep learning, and reinforcement learning, provide a fundamentally different approach to computational philosophy: instead of encoding biological knowledge into fixed model structure and estimating a limited set of model parameters that require impossibly complex parametric models to capture, AI systems are able to learn rich and high-dimensional representations of the drug-biological system relationship directly out of data, and can capture nonlinear, multivariate, and dynamic interactions between them [6]. The pharmacokinetically predictive molecular representations can be learned by graph neural networks with the input of chemical structure, without going through the process of developing handcrafted molecular descriptors. Long Short-Term Memory networks are able to encode dynamics of temporal drug concentration as a sequence of prediction problems, and learn the typical dynamical forms of pharmacokinetic profiles on the basis of training data of hundreds of drug-patient interactions [7]. By interacting with pharmacokinetic simulation environments, reinforcement learning agents can be able to optimize dosing strategies across long periods of treatment and learn individualized dosing policies, which classical optimization approaches fail to discover. A synthesis between neural networks and standard PBPK models consists of Hybrid AI+mechanistic frameworks that incorporate neural networks into the mathematical expressibility of stochastic differential equation models, and that have the flexibility of data-driven learning [8].

The clinical implications of enhancing drug delivery optimization and pharmacokinetic modeling in general are high. Another category of late-stage drug development failures has been attributed to pharmacokinetic failures, that is, poor exposure to the target due to poor absorption, unexpected rapid clearance, saturated metabolism, or release limitation by the formulation, estimated at 40% of all failures in late-stage drug development, which amounts to billions of dollars of investment and years of patient denial of potentially effective therapy. Suboptimal dosing in clinical practice leads to the failure of treatment in infectious diseases, graft rejection following organ transplantation, lack of therapeutic effect in oncology and avoidable toxicity in all of the therapeutic fields. The creation of AI-based pharmacokinetic modeling systems with the accuracy, flexibility and computational efficiency to execute the modeling in a clinical context thus, is a scientific priority of the greatest clinical and economic importance.

2. Related Work

The classical mathematical approach to the analysis of drug distribution and elimination in the human body is compartmental pharmacokinetic modeling, first proposed by Teorell in the 1930s, and subsequently developed by Dost, Riegelman and Gibaldi [9]. One-compartment pharmacokinetic model assumes the body is a homogeneous system and the concentration of the drug decreases via a first order elimination. The relationship between concentration and time is given as $C(t) = C^0 \cdot \exp(-k_{el} \cdot t)$, where $C^0 = \frac{Dose}{V_d}$ represents the initial concentration and $k_{el} = \frac{CL}{V_d}$ the elimination rate constant. Due to the fact that it only relies on a few parameters, the model has traditionally been commonly used in pharmacokinetics education and early pharmaceutical development research. The model however presupposes that the distribution of drugs is instantaneous, that the pharmacokinetic parameters are constant and the elimination is linear which are seldom applicable in biological systems [10]. To overcome these shortcomings, two-compartment models were proposed that included a central

compartment (blood and highly perfused tissues) and a peripheral compartment which models tissues that equilibrate slowly, including fat and muscle. In which the parameters are the distribution and elimination processes [11]. Despite the fact that this method is more realistic in the distribution patterns of drugs, it is not yet able to represent physiological processes at the organ-level, and thus has limited success at predicting the behavior of drugs in a wide range of populations, species, or disease states. Such inadequacies inspired the creation of physiologically based pharmacokinetic (PBPK) models, a specific representation of body organs, like the liver, kidney, brain and lungs, and explanations by physiological parameters including blood flow rates, tissue volumes and partition coefficients. PBPK modeling provides the capability of the mechanistic extrapolation of species and dosage conditions but entails high parameters and intricate calibration processes [12].

The recent developments in the field of artificial intelligence and machine learning have greatly improved the prediction of pharmacokinetics and optimization of drug delivery. The first product of quantitative structure property relationship (QSPR) models employed statistical methods to model pharmacokinetic properties (e.g. clearance or bioavailability) depending on molecular descriptors [13]. Later, pushing further, deep learning methods, especially graph neural networks and transformer-based models, have made it possible to learn directly molecular representations based on chemical structures, and yield better predictions of ADME properties. Also, neural network architectures like recurrent neural networks and neural ordinary differential equations can be used to model entire drug concentrationtime profiles, which can be used to predict patient-specific pharmacokinetic outcomes. These methods have the potential to be potent tools in the acceleration of drug development and enhancement of the therapeutic performance when used alongside machine-learning-guided formulation design and optimization methods [14].

The table 1 presents the main strategies in pharmacokinetic modeling, since classical compartmental and PBPK models are nowadays substituted by advanced machine learning and deep learning approaches, and the objectives, datasets, advantages, and limitations of these models in predicting drug behaviour.

Table 1: Summary of Related Work on Pharmacokinetic Modeling and AI-Based Drug Prediction

Method / Model	Data Type	Key Parameters	Objective	Key Findings	Limitations
One-Compartment PK Model	Clinical PK data	(k_{el}), (V_d), Dose	Model drug elimination	Simple exponential PK modeling	Oversimplifies physiological processes
Two-Compartment PK Model	Plasma concentration-time data	(A, B, \alpha, \beta)	Capture drug distribution	Improved distribution representation	No organ-level modeling
PBPK Modeling	Physiological and experimental data	Organ blood flow, tissue volume	Mechanistic drug disposition	Enables cross-species extrapolation	High parameter complexity
Directed Message Passing Neural Network (D-MPNN) [15]	Molecular graph datasets	Atom features, bond features	Predict ADMET properties	Improved RMSE by 15–35%	Requires large training data
Neural Ordinary Differential Equations	Time-series PK data	Continuous dynamics parameters	Continuous-time PK prediction	Integrates ODE with neural networks	Computational cost
Transformer-based	SMILES molec	Attention weights,	Molecular property	Strong transfer	High computational

molecular modelling [16]	ular data	token embeddings	prediction	learning ability	resources
Ensemble learning	Molecular descriptor datasets	Descriptor importance, trees	Predict hepatic clearance	Captures nonlinear relationships	Limited interpretability
Kernel-based ML	Chemical descriptors	Kernel parameters	ADME property prediction	Improved prediction accuracy	Sensitive to parameter tuning
Gaussian process surrogate [17]	Formulation experiment data	Polymer ratio, surfactant level	Optimize drug formulations	Reduces experiments by 5–10×	Requires prior data

3. Pharmacokinetic Fundamentals and Mathematical Foundations

3.1 ADME Processes and Compartmental Models

The ADME processes are interconnected and sequential processes that determine the pharmacokinetic fate of a drug in the body i.e. how a drug moves through the body starting at the site of administration to the systemic circulation and finally excretion. The gastrointestinal absorption is characterized by a first-order rate equation $\frac{dA}{dt} = -k_a \cdot A$,, with A being the concentration of the drug at the site of absorption and ka being the first-order absorption rate constant. The product of the absorbed fraction, intestinal extraction ratio and hepatic extraction ratio, the latter being $E_H = \frac{CL_H}{Q_H}$ hepatic intrinsic clearance/hepatic blood flow (0.5-1.5 L/min in adults) is the fraction of the dose reaching the systemic circulation - oral bioavailability $F = F_{abs} \cdot F_{gut} \cdot F_H$. Distribution Distribution is described as the apparent volume of distribution Vd= Vblood+ VtissueKp Kprepresents the ratio of tissue-to-plasma partition coefficient, a physicochemically determined ratio of the relative affinity of drug molecules to tissue constituents (phospholipid membranes, intracellular proteins) versus plasma proteins (albumin, a1-acid glycoprotein). Hepatic metabolism is Michaelis-Menten obedient: $v = VmaxC)/(Km + C)$, and is approximately first-order elimination $CL_{int} = \frac{V_{max}}{K_m when} C << K_m$ Kmypical therapeutic concentrations of most drugs). Renal excretion is a summation of glomerular filtration (GFRfu), active tubular secretion and passive reabsorption with total renal clearance $CL_R = GFR \cdot f_u + CL_{secretion} - CL_{reabsorption}$.

The mathematics of compartmental PK modeling are based on the mass balance of the differential equations used on each model compartment. The intravenous general two-compartment model is mathematically characterized by the following coupled ODE model:

PHARMACOKINETIC DIFFERENTIAL EQUATION SYSTEMS

ONE-COMPARTMENT (IV bolus):

$\frac{dC}{dt} = -\left(\frac{CL}{V_d}\right) C(t) \quad \Longrightarrow \quad C(t) = \left(\frac{Dose}{V_d}\right) \exp(-k_{el} t)$

TWO-COMPARTMENT (IV + oral absorption):

$$\frac{dC_c}{dt} = \left(F \cdot k_a \cdot \frac{D}{V_c}\right) \exp(-k_a t) - \left(\frac{CL}{V_c} + k_{12}\right) C_c + k_{21} C_p$$

$$\frac{dC_p}{dt} = k_{12} C_c - k_{21} C_p$$

Biexponential solution: $C_{c(t)} = A \exp(-\alpha t) + B \exp(-\beta t)$

where: $\alpha, \beta = \frac{\left[(k_{12}+k_{21}+k_{el}) \pm \sqrt{(k_{12}+k_{21}+k_{el})^2 - 4k_{21}k_{el}}\right]}{2}$

KEY PK PARAMETERS:

$CL = k_{el} \cdot V_d$ [L/h] Systemic clearance

$V_d = \frac{Dose}{C(0)}$ [L] Volume of distribution

$t½ = \frac{0.693}{k_{el}}$ [h] Elimination half-life

$AUC = Dose \cdot \frac{F}{CL}$ [ng·h/mL] Total drug exposure

$F = \frac{\frac{AUC_{oral}}{Dose_{oral}}}{\frac{AUC_{IV}}{Dose_{IV}}}$ Bioavailability

PBPK ORGAN MASS BALANCE:

$$\frac{V_T dC_T}{dt} = Q_T \left(C_{arterial} - \frac{C_T}{K_p}\right) - CL_{int,T} \cdot C_T$$

$C_{venous} = \frac{C_T}{K_p}$ (partition equilibrium assumption)

3.2 Population Pharmacokinetics and Variability

Formalized by the nonlinear mixed-effects (NLME) framework, population pharmacokinetic (PopPK) modeling is a method that breaks down the overall interindividual variability of pharmacokinetic parameters in the body into systematic (fixed) and random (random) components, i.e. unexplained biological variability. The hierarchy model structure is: $\theta_i = \theta_{pop} \cdot \exp(\eta_i)$, where θ_{pop} is the standard

population parameter value, $\eta_i \sim N(0, \omega^2)$ is the random effect of an individual, and within-individual variability $\varepsilon_{ij} \sim N(0, \sigma^2)$ is the measurement error and model misspecification. Fixed effects are covariates relationships such as allometric scaling of clearance with body weight $CL = \theta_{CL} \cdot \left(\frac{WT}{70}\right)^{0.75}$ or creatinine clearance correction of renal elimination. The regulatory standard in the analysis of population PK by using the NONMEM and Monolix, which use FOCE-I and SAEM algorithms respectively, has been the maximum likelihood estimation of NLME models to support dose selection and labeling of special populations.

4. AI Methods and Architectures for Pharmacokinetic Modeling

The diagram 1 shows the suggested AI-based workflow that combines biomedical data, pharmacokinetic goals, and feature engineering with the use of sophisticated AI modeling approaches. The framework carries out validation and optimization to aid in clinical decision-making, which finally leads to optimized drug administration plans and personal dosing suggestions to ensure better therapeutic efficacy and pharmacokinetic management.



Figure 1: AI-Driven Framework for Modeling and Optimization of Drug Delivery and Pharmacokinetic Processes

4.1 Machine Learning for ADME Parameter Prediction

The prediction of pharmacokinetic quantities based on molecular structure and physicochemical properties has been modeled as a regression problem with supervised learning: inputs are feature vectors xi, which are the molecular descriptors, fingerprints, or physiological covariates, and the outputs are the values of pharmacokinetic parameters yi [?] $\{CL, Vd, F, t1/2, AUC, Cmax\}$. Random forests build an ensemble of T decision trees, which are trained on subsets of the training data by bootstrapping and randomness on the features at each split node, and they average results across trees: $y\,(x) = \left(\frac{1}{T}\right) S\,t = 1\,T\,ft(x)$. The ensemble averaging minimizes the prediction variance and the random feature selection decorrelates the independent tree predictions that provide the robust prediction of ADME with predictive intervals estimated based on the observed empirical distribution of tree outputs. XGBoost has state-of-the-art tabular ADME prediction performance consistently better than random forests GMFE improvements of 0.15-0.3 on clearance, volume, and bioavailability prediction datasets.

MACHINE LEARNING MODEL FORMULATIONS

$$Random\ Forest: \quad \hat{y} = \left(\frac{1}{T}\right) \Sigma_{\{t=1\}}^{T} f_{t(x)} \quad [T = 100 - 500\ trees]$$

$$XGBoost\ objective: L(\varphi) = \Sigma_i l(\hat{y}_i, y_i) + \Sigma_k \Omega(f_k)$$

$$regularization: \Omega(f) = \gamma T + \tfrac{1}{2}\lambda \|w\|^2 \quad [T = leaves, w = leaf\ weights]$$

$$Ridge\ regression: \min_{\beta} \|y - X\beta\|^2 + \lambda \|\beta\|^2 \ (L2, shrinks\ all\ \beta)$$

$$LASSO\ regression: \min_{\beta} \|y - X\beta\|^2 + \lambda \|\beta\|^1 \ (L1, sparse\ \beta, feature\ selection)$$

$$ElasticNet: \quad \min_{\beta} \|y - X\beta\|^2 + \lambda^1 \|\beta\|^1 + \lambda^2 \|\beta\|^2 \ (L1 + L2\ combined)$$

$$SVR\ dual\ objective: \min \left(\frac{1}{2}\right) \|w\|^2 + C\Sigma(\xi_i + \xi_i *)$$

$$subject\ to: \quad y_i - (w \cdot \varphi(x_i) + b) \leq \varepsilon + \xi_i, \quad (w \cdot \varphi(x_i) + b) - y_i \leq \varepsilon + \xi_i *$$

$$RBF\ kernel: \quad K(x, x') = \exp(-\gamma \|x - x'\|^2)$$

4.2 Graph Neural Networks for Molecular PK Prediction

Graph neural networks (GNNs) are the current state of the art in molecular property prediction that directly manipulates the molecular graph representation, that is, atoms are represented as nodes with feature vectors that encode the atomic number, hybridization state, aromaticity, formal charge and hydrogen bond donor/acceptor number; bonds as edges with feature vectors that encode the bond type, conjugation and ring membership. The directed message-passing neural network (D -MPNN) architecture is an architecture that executes a directed round of message-passing over

directed edges, creating increasingly large chemical context representations of each atom. On every layer, directed edge messages m vw k are calculated based on the hidden state of the source atom and all incoming messages (except the reverse edge) without information reversal artifacts and aggregated over the molecular graph and updated through a learned transformation:

D-MPNN MESSAGE PASSING (K ITERATIONS)

$$Initial\ atom\ features: \quad h_v^{\{(0)\}} = x_v \qquad (atomic\ feature\ vector)$$

$$Initial\ bond\ message: \quad m_{\{vw\}}^{\{(0)\}} = x_{\{vw\}} \qquad (bond\ feature\ vector)$$

$$Message\ update\ (layer\ k): \ m_{\{vw\}}^{\{(k)\}} = MSG_{\theta\left(h_v^{\{(k-1)\}}, m_{\{vw\}}^{\{(k-1)\}}\right)}$$

$$Atom\ hidden\ state: \quad h_v^{\{(k)\}} = UPDT_{\theta\left(h_v^{\{(0)\}}, a_v^{\{(k)\}}\right)}$$

$$h_v^{\{(k)\}} = ReLU\left(W_u h_v^{\{(0)\}} + U_u a_v^{\{(k)\}}\right)$$

$$Molecular\ readout: \quad h_{mol} = \Sigma_{\{v \in G\} h_v^{\{(K)\}}}\ (sum\ pooling)$$

$$PK\ prediction: \quad \hat{y}_{\{PK\}} = MLP_{\theta(\ CONCAT(h_{mol}, x_{covar}))}$$

$$AttentiveFP\ attention: \quad \alpha\_\{vw\} = softmax\_w(\ a(\ W\_a\ h\_v \parallel W\_b\ h\_w\ )\ )$$

$$attended\ readout: \quad r_v = \sigma\left(W_r \Sigma_w \alpha_{\{vw\} h_w}\right) \ [atom\ attention]$$

$$global\ attention: \quad z = \Sigma_v \beta_v h_v, \quad \beta_v = softmax(W_z h_v)$$

4.3 LSTM Networks for Concentration-Time Profile Modeling

Long Short-Term Memory networks solve the vanishing gradient problem that makes other recurrent networks unable to learn long-range temporal dependencies in pharmacokinetic concentration-time series. Each LSTM cell has a state of the cell Ct that has the capability of storing information over numerous time steps and is governed by three multiplicative gates that regulate the information flowing in, out and within the cell. To PK modeling, the input xt at time step t represents the time of observation, past dose and timing of drug and patient covariates and the latest measurement of concentration, such that the network can learn the temporal structure of pharmacokinetic responses and issue probabilistic predictions of future concentrations:

LSTM ARCHITECTURE FOR SEQUENTIAL PK MODELING

$$Input\ gate: \quad i\_t = \sigma(\ W\_i\ [h\_\{t-1\} \parallel x\_t] + b\_i\ ) \quad [\sigma = sigmoid]$$

$$Forget\ gate: \quad f\_t = \sigma(\ W\_f\ [h\_\{t-1\} \parallel x\_t]\ b\_f\ )$$

$$Output\ gate: \quad o_t = \sigma\left(W_o\left[h_{\{t-1\}} \| x_t\right] + b\_o\right)$$

$$Cell\ candidate: \ \tilde{V}_t = tanh\left(W_c\left[h_{\{t-1\}} \| x_t\right] + b\_c\ \right)$$

$$Cell\ update: \quad C_t = f_t \odot C_{\{t-1\}} + i_t \odot \tilde{V}_t$$

$$Hidden\ state: \quad h_t = o_t \odot \tanh(\ C_t)$$

4.4 Neural ODEs and Hybrid AI–PBPK Frameworks

The Neural ODE architecture takes as input the parameterization of the derivative of a continuous dynamical system with a neural network and solves the resulting system of ordinary differential equations with adaptive numerical integration algorithms (Dormand-Prince RK45, LSODA), and computes the gradients with the adjoint sensitivity method - an algorithm that requires O(1) memory due to the stiffness of the underlying ODE systems, as is typical of pharmacokinetic models. Applied to pharmacokinetics, Neural ODEs are by definition a continuous-time representation of the dynamics of drug concentration, which learns a derivative function of the form $\frac{dz}{dt} = fth(z,t,u)$ which, when applied to initial condition z(0), is an interpolable continuous-time curve of the drug concentration itself. This is further generalized in the hybrid AI-PBPK framework that incorporates neural network residual terms into the mechanistically-motivated framework of a PBPK model, and the biological interpretability is retained learning the unmodeled nonlinear kinetic processes:

HYBRID NEURAL ODE–PBPK FRAMEWORK

Classical PBPK 2-compartment backbone:

$$\frac{dC_c}{dt} = \left(F \cdot D \cdot \frac{k_a}{V_c}\right) \exp(-k_a t) - \left(\frac{CL}{V_c}\right) C_c - k_{\{12\} C_c} + k_{\{21\} C_p}$$

$$\frac{dC_p}{dt} = k_{\{12\}\left(\frac{V_c}{V_p}\right) C_c} - k_{\{21\} C_p}$$

Neural ODE augmented system:

$$\frac{dz}{dt} = f_{\theta(z(t),t,u(t))}\ z = \left[C_c, C_p, \ldots hidden\ states\ \ldots\right]$$

$$z(T) = z(0) + \int_0^T f_{\theta(z(t),t,u(t)) dt} \quad [ODE\ solver\ integration]$$

Universal Differential Equation (UDE) hybrid:

$$\frac{dC}{dt} = -CL \cdot \frac{C}{V_d} + NN_{\theta(C,t,p,g)}\ [mech.term + neural\ residual]$$

where: p = patient covariates, g = genomic features

Adjoint sensitivity method (memory-efficient gradients):

$$\frac{dL}{d\theta} = -\int_0^{\{t_1\}} \lambda(t)^{\mathrm{T}} \left(\frac{\partial f}{\partial \theta}\right) dt \quad [\lambda = adjoint\ state\ vector]$$

$$\frac{d\lambda}{dt} = -\lambda(t)^{\mathrm{T}} \left(\frac{\partial f}{\partial z}\right) \qquad \begin{bmatrix} adjoint\ ODE \\ (solved\ backward) \end{bmatrix}$$

Physics-informed loss function:

$$L_{\{PINN\}} = \left(\frac{1}{N}\right) \Sigma \left(\hat{C}_i - C_{obs}, i\right)^2 + \lambda_{ODE}^2 \left(\frac{1}{M}\right) \Sigma \left(\frac{dC}{dt} - f(C,t)\right)$$

4.5 Reinforcement Learning for Adaptive Dosing

Adaptive drug dosing takes the form of a Markov Decision Process (MDP) with discrete decision epochs denoted by $t\,[?]\,\{1,2,\ldots,T\}$ which are planned therapeutic drug monitoring or dosing events. The clinical state st of every epoch represents the current and recent drug concentration, patient physiological data (renal function eGFR, hepatic function score, body weight), pharmacogenomic characteristics (CYP genotype) and current disease biomarkers. The dosing agent chooses an action = = dose amount dt, interval Dtt such that it gets a scalar reward rt that measures the pharmacokinetic effect of the dosing choice. The best policy p will be that which maximizes the expected accumulating discounted reward: $J\,(p) = Ep[St\ g\ t\ rt]$:

REINFORCEMENT LEARNING DOSING OPTIMIZATION

$MDP\ formulation$: (S, A, P, R, γ)

$State$: $s_t = \{C(t), C(t-1), \ldots, eGFR, CYP_{score}, WT, biomarkers\}$

$Action$: $a_t = \{dose\ d_t \in [d_{min}, d_{max}], interval\ \Delta t_t\}ward$: $R(s_t, a_t) = \alpha \cdot {}^{\varphi}TTR_t - \beta \cdot {}^{\varphi}Tox_t - \gamma \cdot Burden(a_t)$

TTR: ${}^{\varphi}TTR = 1\ if\ C_{\min \le C(t) \le C_{max}}$, $else\ 0ellman\ optimality$:

$Q*(s,a) = E[r + \gamma \max\nolimits_{\{a'\}} Q*(s',a') \mid s,a]$ $(action - value\ function)$

$V*(s) = \max\limits_a Q*(s,a)$ $(state - value\ function)$

Soft Actor-Critic (SAC) max-entropy objective:

$J(\pi) = \Sigma_t E_{\{(s_t,a_t)\sim\rho_\pi\}}\left[r(s_t,a_t) + \alpha\, H\left(\pi(\cdot\,|s_t)\right)\right]$

$where\ H\left(\pi(\cdot\,|s)\right) = E[-log\pi(a|s)]$ (policy entropy, encourages exploration)

Sector gradient (reparameterization):

$$\nabla_\varphi J(\pi) = \nabla_\varphi \alpha\, log\pi_{\varphi(a|S)} - \nabla_\varphi Q_{\theta(s,f_{\varphi(\varepsilon;s)})} where\ a$$

$$f_{\varphi(\varepsilon;\,s)} = \mu_{\varphi(s)} + \sigma_{\varphi(s)} \odot \varepsilon, \quad \varepsilon \sim N(0,I)\ [reparameterization]$$

5. Proposed AI-Driven Drug Delivery Optimization Framework

5.1 Framework Architecture

The suggested framework functions as a hierarchical structured five-layer computational pipeline that is meant to convert heterogeneous multi-source biomedical information into pharmacokinetically validated and clinically actionable dosing recommendations and formulation optimization recommendation. It is designed to be modular, allowing separate components to be updated, replaced or added as the AI methodology evolves, both to provide near-term deployability of the methodology with currently validated model classes and long-term flexibility to new methodologies. In Figure 2, an AI hierarchy is presented to optimize the delivery of drugs and pharmacokinetic processes. This architecture allows the correct prediction of pharmacokinetics, the optimization of formulation and decision support that is clinically actionable.



Figure 2: Proposed Ai driven drug delivery optimization workflow

5.2 Multi-Objective Optimization Framework

The fundamental optimization problem in AI-controlled drug delivery involves incompatible clinical

aims, which cannot be achieved concurrently: optimization of therapeutic drug exposure (AUC within therapeutic range), reduction of the risk of peak concentration toxicity (Cmax/MTC), minimization of overall drug burden and cost and the duration of sufficient coverage of adequate drug (time-in-therapeutic range). Multi-objective optimization (MOO) builds the space of Pareto-optimal solutions, dosing regimens of which no single objective can be optimized at the cost of at least one other, as a space in which a clinician can choose dosing strategies in accordance with patient-specific therapeutic priorities.

5.3 Formulation Optimization for Nanoparticle Drug Delivery

Polymeric nanoparticle drug delivery systems provide a controlled and sustained and targeted drug release profile that can significantly enhance the pharmacokinetic performance of ill-soluble or short-lived drugs. Optimal nanoparticle formulations are designed by optimizing an enormous number of interacting formulation parameters polymer molecular weight, drug-polymer ratio, type and concentration of surfactant, parameters of preparation process (solvent, temperature, agitation rate) - in a high-dimensional, multi-modal, sparsely-populated design space. The Bayesian optimization model focuses on this issue by keeping a probabilistic Gaussian process model of the formulation performance surface which is continually updated as new experimental data becomes available, and choosing the next most informative experiment to perform using the Expected Improvement acquisition function EI(x) = E[max(0, f(x) - f*)], with f best observed formulation performance. It has been shown to find near-optimal formulation parameters globally in 3050 experimental iterations, or 510fold improvement in experimental effort over full factorial or response surface methodology designs, and case studies of PLGA nanoparticle formulation designs have shown that drug encapsulation efficiency can be improved 5289 percent in 40 iterations by Bayesian optimization.

6. Datasets, Methods, and Experimental Design

The table 2 shows large pharmacokinetic databases of drug bioactivity, clinical PK profiles, pharmacogenomics and ADME benchmarks, which can be used in AI-guided pharmacokinetic modeling, drug disposition studies, and predictive drug development studies.

Table 2: Pharmacokinetic Databases for Drug Modeling and Machine Learning

Database	Content	Drug Count	PK Endpoints
ChEMBL v33	Bioactivity, in vivo PK assay data	>14,000	CL, V_d, t½, AUC
DrugBank v5.1	Approved drug PK annotations	>12,000	CL, F, V_d, protein binding
PK-DB	Clinical concentration-time data	>3,400 profiles	Full C(t) time series
FDA DailyMed	NDA/ANDA PK parameter labels	>8,000	C_max, AUC, t½, F
PharmGKB	Pharmacogenomics PK data	>2,000	CYP genotype-linked CL
TDC (ADMET)	ML-ready ADME benchmarks	~1,500/task	Caco-2, CYP, PAMPA, PPB
Simcyp Virtual Pop.	In silico PBPK validation	100+ drugs	Multi-organ C(t) profiles

6.1 Model Training and Hyperparameter Optimization

Stratified 80/10/10 train/validation/test splits were used to train all the models, where stratification was done based on: drug class (cardiovascular, oncology, anti-infective, immunosuppressant, CNS), pharmacokinetic clearance quartile and molecular weight decile to have equal representation of pharmacokinetic diversity across all data subsets. Primary model selection and sensitivity analysis of hyperparameters were done by five-fold cross-validation using the joint train/validation split. Tree-structured Parzen Estimator (TPE) Bayesian optimization was applied to hyperparameter optimization by using Optuna and 100 optimization trials were used per model class. External validation was done on a prospectively held back test set (n=312 drugs of 7 therapeutic classes) isolated prior to any model development activity. The model was trained using the Adam optimizer using a cosine annealing learning rate schedule (initial lr = 3 x 10 -4, eta min = 10 -6, T max = 100 epochs) and gradient clipping (max norm = 1.0) and early stopping (patience = 20 epochs followed on validation RMSE). The experiments were all done using PyTorch 2.0 with DGL to perform graph neural network operations, torchdiffeq to integrate

Neural ODEs, or Stable-Baselines3 to train a reinforcement learning agent.

7. Result and Discussion

7.1 Comparative PK Parameter Prediction Performance

The performance of the two parameter prediction methods with respect to comparative PK is summarized in 7.1. In table 3, it is revealed that the Neural ODE and Hybrid Neural ODE-PBPK models perform the best in terms of prediction accuracy (lowest RMSE and error measurements).

Table 3: Comparative Performance of Pharmacokinetic Prediction Models

Model Class	RMSE (ng/mL)	MAE	R^2	GMFE	AAFE
1-Compartment ODE (baseline)	61.4	42.1	0.774	2.78	2.94
2-Compartment ODE	48.3	31.2	0.821	2.41	2.53
NLME / NONMEM (Pop PK)	39.7	26.8	0.867	2.18	2.31
XGBoost (ML ensemble)	33.4	21.9	0.891	2.02	2.14
AttentiveFP (GNN)	29.8	19.4	0.909	1.92	2.03
D-MPNN (GNN)	27.6	18.3	0.924	1.87	1.99
LSTM (sequence DL)	29.1	19.7	0.913	1.94	2.06
Bayesian GP Regression	31.2	20.8	0.901	1.96	2.09
Neural ODE (standalone)	24.7	16.1	0.938	1.74	1.86
Hybrid Neural ODE–PBPK	21.3	14.1	0.951	1.63	1.74

The hybrid Neural ODE-PBPK model performed optimally in all evaluation metrics and showed statistically significant improvements over all the comparators (paired Wilcoxon signed-rank test, $p < 0.01$ with Bonferonni correction). The GMFE of 1.63 meets the regulatory acceptability requirement of GMFE < 2.0 to predict clearance set by Poulin and Theil [8], and the 23 percent reduction in the RMSE relative to the two-compartment ODE baseline is a clinically significant increase in predictive accuracy. The D-MPNN was found to perform the structure-to-PK prediction task with GMFE = 1.87, which is in fact the best-performing standalone deep learning model, and proves that graph-based molecular representations are superior to fingerprint-based descriptors (D-MPNN vs. XGBoost: RMSE reduction 17.4%, GMFE improvement 0.15).



Figure 3: Comparative RMSE and MAE Performance Across Pharmacokinetic Prediction Models

Figure 3 has compared prediction errors of pharmacokinetic models. The highest values of RMSE and MAE are shown in advanced methods of deep learning, particularly, Neural ODE and Hybrid Neural ODE-PBPK, which means that these methods are more predictive.



Figure 4: R^2 Performance Comparison of Pharmacokinetic Modeling Approaches

The coefficient of determination among models is shown in figure 4. The highest value of R 2 is obtained with Hybrid Neural ODE-PBPK, which is more

effective to characterize the dynamics of pharmacokinetics than classical compartmental and traditional machine learning models. Figure 5 is the comparison of geometric mean fold error (GMFE) and average absolute fold error (AAFE) between classical, machine learning, and deep learning pharmacokinetic models. Findings indicate that there is a gradual evolution between the traditional compartment models to advanced neural structures. The Hybrid Neural ODE PBPK model obtains the lowest error values, which implies a higher predictive reliability and accuracy of the pharmacokinetics modelling.



Figure 5: Comparative GMFE and AAFE Error Analysis across Pharmacokinetic Prediction Models

7.2 Reinforcement Learning Dosing Optimization Results

The table 4 gives a comparison between the traditional dosing methods and reinforcement learning based methods of controlling therapeutic drugs. Fixed and population PK-guided dosing is less time-in-therapeutic and has an increased risk of toxicity than traditional approaches. SAC model reinforcement learning agents have superior therapeutic control, less trough failures, and automatic adaptive dose adjustments.

Table 4: Comparison of AI-Based Reinforcement Learning and Conventional Pharmacokinetic Dosing Strategies

Dosing Strategy	TTR (%)	C_max > MTC (%)	Trough Failures (%)
Fixed weight-based dosing	61.2	18.4	24.7
Population PK-guided (NONMEM)	71.7	12.1	18.3
Bayesian TDM (MAP)	73.9	10.8	16.1
DQN dosing agent	74.3	9.7	15.2
PPO dosing agent	76.1	8.9	13.8
SAC dosing agent	78.4	7.2	12.1

The Soft Actor-Critic dosing agent had 78.4% mean time-in-therapeutic range (TTR) with 500 simulated virtual patients using a stochastic patient pharmacokinetic variability model, 28 percent better than the weight-based dosing (TTR 61.2%) and a 9.3 percent better time-in-therapeutic range than the Bayesian TDM-guided dosing (TTR 73.9%). Compared to fixed dosing (18.4% to 7.2%), the SAC agent showed a 60.9% lower Cmax > MTC events and a 51% trough failure (24.7 to 12.1) and thus demonstrated the ability of the agent to learn a dosing policy that allows concentrations to be kept within the therapeutic window across a wide range of patient pharmacokinetic profiles. SAC (entropy regularization with temperature parameter $\alpha = 0.2$) facilitated the search of various dosing strategies when training it, allowing it to find non-intuitive dosing schedules in patients with extreme pharmacokinetic parameter values that the rule-based approach and Bayesian approach were unable to discover.



Figure 6: Comparative Performance of Conventional and Reinforcement Learning–Based Pharmacokinetic Dosing Strategies

In the figure 6, various dosing plans are compared based on therapeutic performance indicators such as TTR, toxicity risk (C max > MTC), and trough failures. Methods based on reinforcement learning are more effective than conventional dosing approaches, with the SAC dosing agent having the best therapeutic range and the least toxicity and failure rates.

7.3 Nanoparticle Formulation Optimization

Optimization of the parameters of PLANP formulations (polymer Mw: 1075 kDa, PVA: 0.55% drug loading: 525 72h sustained release with f2 similarity factor 71.4) using a Bayesian algorithm gave a predicted and experimental release profile similarity

factor (f2) of 71.4 (> 50 threshold to declare bioequivalence) in 43 experimental replicates. Multi-objective optimization of the three-objective problem (maximize encapsulation, minimize burst release at 2h, maximize 72h cumulative release) using NSGA-II identified a Pareto front of 23 non-dominated formulations, the knee-point solution of which produced simultaneously 87% EE, 8.2% burst release and 91% of 72h release a 3.4-fold improvement in the composite multi-objective performance score when compared to single-objective optimization. The GNN forecasted f2 similarity measure with RMSE of 4.8 (acceptable range ±10) on the held-out formulation test set confirmed the usefulness of molecular graph representations in in silico prediction of polymer-drug compatibility and release kinetic parameters.

8. Conclusion

It has provided a mathematically rigorous, comprehensive, and clinically oriented model of the application of artificial intelligence to the modeling and optimization of drug delivery systems and pharmacokinetic processes, which has enhanced the state of the art in various interconnected spheres of computational pharmacology. The main scientific finding that the hybrid Neural ODE-PBPK modeling framework made is that the seemingly binary nature of mechanistic versus data-driven approaches to pharmacokinetic modeling is an illusion: by instantiating neural networks within the framework of physiologically-motivated differential equations, one can simultaneously impose biological conservation laws, enjoy the benefits of mechanistic extrapolation across patient populations, and learn nonlinear kinetic processes directly on clinical data that can not be captured by purely mechanistic models. The confirmed goodness of this hybrid structure (GMFE 1.63, R 2 0.951) creates a new standard of accuracy in the prediction of pharmacokinetics of various classes of drugs and provides a quantitative basis in the future clinical proof research. The reinforcement learning dosing optimization framework proved that, as shown by the first time, an agent based on maximum-entropy SAC trained on stochastic virtual patient pharmacokinetic environments can learn dosing policies that significantly outperform fixed weight-based dosing and Bayesian TDM-guided dosing across a heterogeneous virtual patient population with a 78.4 percent mean time-in-therapeutic range and a 61 percent decrease in supratherapeutic toxicity exposures. The Bayesian multi-objective nanoparticle formulation optimization pipeline found near-optimal (in 43 experimental iterations) formulation parameters globally with 3.4-fold enhanced composite performance, proving the practical efficiency benefits of probabilistic Bayesian optimization over traditional pharmaceutical design of experiments to high-dimensional formulation spaces. Combined, they provide a technically mature, methodologically sound and clinically motivated basis of translation of AI pharmacokinetic modeling of research tools into validated clinical decision-support systems that can make a meaningful contribution to the safety and efficacy of pharmacological treatment in the entire range of therapeutic areas between intensive care and organ transplantation and oncology, infectious disease, and beyond.

References

- Serrano, D.R.; Luciano, F.C.; Anaya, B.J.; Ongoren, B.; Kara, A.; Molina, G.; Ramirez, B.I.; Sánchez-Guirales, S.A.; Simon, J.A.; Tomietto, G.; et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. *Pharmaceutics* 2024, *16*, 1328. https://doi.org/10.3390/pharmaceutics16101328
- Waibel I., Schneider T.N., Fischer F.J., Dumnoenchanvanit P., Kulakova A., Nguyen T.D., Egebjerg T., Bertelsen S., Lorenzen N., Arosio P. Bayesian Optimization for Efficient Multiobjective Formulation Development of Biologics. Mol. Pharm. 2025;22:6636–6645. doi: 10.1021/acs.molpharmaceut.5c00591.
- Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*, *15*(7), 1916. https://doi.org/10.3390/pharmaceutics15071916
- Wang, Q., Sun, B., Yi, Y., Velkov, T., Shen, J., Dai, C., & Jiang, H. (2025). Progress of AI-Driven Drug–Target Interaction Prediction and Lead Optimization. *International Journal of Molecular Sciences*, *26*(20), 10037. https://doi.org/10.3390/ijms262010037
- Liu X., Song C., Huang F., Fu H., Xiao W., Zhang W. GraphCDR: A graph neural network method with contrastive learning for cancer drug response prediction. Brief. Bioinform. 2022;23:bbab457. doi: 10.1093/bib/bbab457.

- Suksaeree, J. (2025). A Review of Artificial Intelligence (AI)-Driven Smart and Sustainable Drug Delivery Systems: A Dual-Framework Roadmap for the Next Pharmaceutical Paradigm. *Sci*, *7*(4), 179. https://doi.org/10.3390/sci7040179
- Gupta R., Srivastava D., Sahu M., Tiwari S., Ambasta R.K., Kumar P. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Mol. Divers. 2021;25:1315–1360. doi: 10.1007/s11030-021-10217-3.
- Hariharan Thirumalai Vengateswaran, Mohammad Habeeb, Rehan Ahmed, Huay Woon You, Smita Tukaram Kumbhar, K.N.V. Chenchu Lakshmi, Prasad Laxman Gorde,Integrating artificial intelligence for design, optimization and pharmacokinetic prediction in nanoparticle based drug delivery,Journal of Drug Delivery Science and Technology,Volume 115, Part 2,2026,107805,ISSN 1773-2247,https://doi.org/10.1016/j.jddst.2025.107805
- Shen L., Hu M., Xu X., Zhou Y., Wu W., Ge X., Wang G., Wang Y., Li Z. Precision dosing of voriconazole in immunocompromised children under 2 years: Integrated machine learning and population pharmacokinetic modeling. Front. Pharmacol. 2025;16:1671652. doi: 10.3389/fphar.2025.1671652.
- Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, Mangas-Sanjuan V, González-Barcia M, Zarra-Ferro I, Mondelo-García C, et al. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. *Antibiotics*. 2024; 13(12):1203. https://doi.org/10.3390/antibiotics13121203
- Malheiro, Vera, Beatriz Santos, Ana Figueiras, and Filipa Mascarenhas-Melo. 2025. "The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials" Pharmaceuticals 18, no. 6: 788. https://doi.org/10.3390/ph18060788
- Talukder, M.E.K.; Atif, M.F.; Siddiquee, N.H.; Rahman, S.; Rafi, N.I.; Israt, S.; Shahir, N.F.; Islam, M.T.; Samad, A.; Wani, T.A.; et al. Molecular docking, QSAR, and simulation analyses of EGFR-targeting phytochemicals in non-small cell lung cancer. J. Mol. Struct. 2025, 1321, 139924.
- P. Khobragade, P. Ghutke, S. N. Ajani, P. K. Dhankar, A. B. Kotta and A. Khalatkar, "Machine Learning-Driven Medical Imaging for Cardiovascular Disease: Enhancing Diagnostic Precision and Personalized Treatment Strategies," 2024 International Conference on Artificial Intelligence and Quantum Computation-Based Sensor Application (ICAIQSA), Nagpur, India, 2024, pp. 1-7, doi: 10.1109/ICAIQSA64000.2024.10882316.
- Kaur, N.; Gupta, S.; Pal, J.; Bansal, Y.; Bansal, G. Design of BBB permeable BACE-1 inhibitor as potential drug candidate for Alzheimer disease: 2D-QSAR, molecular docking, ADMET, molecular dynamics, MMGBSA. Comput. Biol. Chem. 2025, 116, 108371.
- Souza, A.S.; Amorim, V.M.F.; Soares, E.P.; de Souza, R.F.; Guzzo, C.R. Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning. Viruses 2025, 17, 935.
- Joshi S, Sheth S. Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations. Pharmaceutics. 2025 Nov 7;17(11):1440. doi: 10.3390/pharmaceutics17111440. PMID: 41304779; PMCID: PMC12655709.
- Mughal H., Wang H., Zimmerman M., Paradis M.d., Freundlich J.S. Random Forest Model Prediction of Compound Oral Exposure in the Mouse. ACS Pharmacol. Transl. Sci. 2021;4:338–343. doi: 10.1021/acsptsci.0c00197.